CClinicalTrials.gg
RecruitingNCT07696286Updated Aug 12, 2026

Evaluation of Alexithymia in Chronic Pain Patients With Spinal Cord Stimulation

An observational study in Chronic Pain, sponsored by Marmara University. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-12.

Sponsored by Marmara University · Observational

Study type
Observational
Model
Other
Time perspective
Cross-sectional
Enrollment
20
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to investigate the relationship between alexithymia levels and clinical parameters, including pain intensity and quality of life, in chronic pain patients treated with spinal cord stimulation (SCS). Chronic neuropathic pain can lead to psychological distress and decreased quality of life. While SCS is an effective neuromodulation therapy for managing refractory pain, patient outcomes vary significantly, suggesting that biomedically similar patients experience different levels of relief due to psychosocial factors.

Alexithymia, characterized by difficulties in identifying and describing emotions, may significantly influence the individual pain experience and treatment outcomes. In this cross-sectional observational study, patients who underwent SCS implantation for clinical indications will be evaluated. Clinical data regarding pain history will be collected retrospectively from patient files, while psychosocial profiles will be assessed at a single time point using validated psychometric questionnaires. The study aims to contribute to a better understanding of psychosocial variables in neuromodulation outcomes, potentially aiding in improved patient selection and expectation management.

Read the detailed description

Chronic pain is a multidimensional clinical syndrome that can lead to decreased functionality, sleep and mood disorders, loss of social and occupational roles, and a significant reduction in quality of life. In chronic neuropathic pain cases, spinal cord stimulation (SCS) is increasingly used as a neuromodulation-based, reversible, and minimally invasive treatment option. However, responses to SCS in clinical practice are heterogeneous, and functional gains vary among patients with similar biomedical characteristics, suggesting that outcomes are influenced by psychosocial factors.

This single-center, non-interventional, cross-sectional observational analytical study aims to investigate the relationship between alexithymia levels and clinical parameters in chronic pain patients who underwent SCS implantation at the Marmara University Pendik Training and Research Hospital Algology Clinic between January 2023 and May 2026.

Clinical data (Visual Analog Scale/Numeric Rating Scale for pain intensity and SF-12 data) will be collected retrospectively from patient files. Psychometric evaluations will be performed at a single time point using validated self-report questionnaires during a single session lasting approximately 25-35 minutes. No repetitive measurements or follow-up visits are planned for research purposes.

The evaluation tools include:

  1. Sociodemographic Data Form: Captures clinical and demographic characteristics.
  2. Toronto Alexithymia Scale (TAS-20): Assesses difficulties identifying emotions, difficulties describing emotions, and externally-oriented thinking.
  3. Hospital Anxiety and Depression Scale (HADS): Measures anxiety and depression levels to control for mood symptoms as potential confounding factors.
  4. Short Form Health Survey (SF-12): Evaluates health-related quality of life.
  5. Childhood Trauma Questionnaire (CTQ-33): Assesses retrospective childhood and adolescent adverse experiences (emotional, physical, and sexual abuse; emotional and physical neglect; overprotection-control).
  6. Visual Analog Scale (VAS): Measures current pain intensity on a 0-10 cm horizontal line.

The primary objective is to evaluate the relationship between alexithymia levels, pain intensity, and quality of life scales. Secondary objectives include analyzing the relationship between alexithymia and patient-reported outcomes (functionality, pain, and life quality), evaluating the potential confounding effects of childhood trauma and anxiety/depression symptoms on this relationship, and providing insights into how psychosocial factors influence clinical measurement tools.

02

Conditions studied

  • Chronic Pain

Keywords

  • CHRONIC PAIN
  • Spinal Cord Stimulation
  • Alexithymia
  • Quality of Life
  • Childhood Trauma
  • Anxiety and Depression
  • Neuromodulation
03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Chronic pain patients aged 18 and older who have undergone permanent spinal cord stimulation (SCS) implantation due to clinical indications at the outpatient clinic.

Inclusion criteria

  • - Being 18 years of age or older
  • Having undergone permanent spinal cord stimulation (SCS) implantation due to clinical indications
  • Providing written informed consent for study participation
  • Being literate
  • Having the cognitive capacity to complete the psychometric scales
  • No active, severe psychiatric disorders requiring immediate treatment (e.g., schizophrenia, bipolar affective disorder, severe psychotic disorders)

Exclusion criteria

Exclusion Criteria:

  • Cognitive impairment or communication barriers that compromise the capacity to provide informed consent
  • Presence of active psychotic disorders or manic episodes
  • Suspected self-harm or suicide risk during the clinical interview
  • Presence of specific secondary causes that could explain the pain (e.g., active malignancy, active infection, acute fracture)
04

Study design

Observational model
Other
Time perspective
Cross-sectional
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • SCS Chronic Pain Patients

    Chronic pain patients aged 18 and older who have undergone permanent spinal cord stimulation (SCS) implantation due to clinical indications.

    Other: Psychometric Questionnaires and Retrospective Data Collection

Interventions

  • OtherPsychometric Questionnaires and Retrospective Data Collection

    Participants are evaluated at a single time point using self-report questionnaires including the Toronto Alexithymia Scale (TAS-20), Hospital Anxiety and Depression Scale (HADS), Short Form Health Survey (SF-12), and Childhood Trauma Questionnaire (CTQ-33). Pain intensity (VAS/NRS) and clinical data are extracted retrospectively from medical records.

05

What researchers measure

Primary outcomes

  1. Toronto Alexithymia Scale (TAS-20) Score

    A 20-item self-report questionnaire used to assess alexithymia levels. It evaluates three subscales: difficulty identifying feelings, difficulty describing feelings, and externally-oriented thinking. Total scores range from 20 to 100, with higher scores indicating higher levels of alexithymia.

    Time frame: Baseline

Secondary outcomes

  1. Visual Analog Scale (VAS) Score

    A 10 cm horizontal scale used to measure current pain intensity, where 0 represents no pain and 10 represents the most severe pain.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  2. Short Form Health Survey (SF-12) Score

    A 12-item questionnaire used to assess health-related quality of life across 8 dimensions. Total scores range from 0 to 100, with higher scores indicating better quality of life.

    Time frame: Baseline, 1 month, 3 months, and 6 months

  3. Hospital Anxiety and Depression Scale (HADS) Score

    A 14-item self-report scale with anxiety and depression subscales (7 items each). Scores for each subscale range from 0 to 21, with higher scores indicating higher symptom severity.

    Time frame: Baseline

  4. Childhood Trauma Questionnaire (CTQ-33) Score

    A 33-item self-report scale evaluating retrospective childhood and adolescent adverse experiences. Higher scores indicate an increased level of trauma.

    Time frame: Baseline

06

Study locations

1 of 1 sites recruiting
  • Marmara University Pendik Training and Research Hospital
    Istanbul, Turkey (Türkiye)
    Recruiting
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT07696286
Lead sponsor
Marmara University
Responsible party
Haner Direskeneli (Professor, MD, Marmara University) — Principal investigator
First posted
Jul 10, 2026
Start date
Jun 1, 2026
Primary completion
Dec 1, 2026 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
Aug 12, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion